Improving Rare Disease Awareness: Paul Wuh-Liang Hwu, MD, PhD

Video

The professor from National Taiwan University Hospital discussed the importance of Rare Disease Day for raising awareness.

“The first step to work on in rare disorders is the diagnosis. In order to increase diagnoses, we need to increase awareness. In order to increase awareness, I think the best way is better education. So, we need to persuade authorities that this education is very important, and they should represent a certain percentage of their continuing education program to cover those rare disorders.”

Monday, February 28, is international Rare Disease Day. Rare diseases affect over 300 million people worldwide, with over 7000 diseases designated as rare.

Companies are developing gene and cell therapies for rare diseases such as Pompe disease and aromatic L-amino acid decarboxylase (AADC) deficiency, including PTC Therapeutics’ gene therapy PTC-AADC. Paul Wuh-Liang Hwu, MD, PhD, professor of pediatrics, National Taiwan University Hospital, serves as investigator on the PTC-AADC trials.

CGTLive spoke with Hwu about Rare Disease Day, rare disease awareness, and physician education. He also discussed the importance of patient advocacy and the improvements that still need to be made in these areas to advance both our understanding and management of rare diseases.

Recent Videos
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
© 2024 MJH Life Sciences

All rights reserved.